---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-000652"
form_type: "8-K"
ticker: null
cik: "0001029125"
company_name: "Panbela Therapeutics, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:32:57.778262+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Panbela Therapeutics receives Nasdaq delisting notice; bid price below $0.10 for 10 days

## Summary
- On Jan 3, 2023, Nasdaq notified Panbela that its common stock closed at $0.10 or less for 10 consecutive trading days, triggering delisting.
- Trading suspension scheduled for Jan 12, 2023; company requested hearing by Jan 10, 2023 to stay delisting.
- Company also not in compliance with minimum stockholders' equity of $2.5M; extension to Feb 15, 2023.
- Company intends to effect 1-for-40 reverse stock split (previously approved) and take other measures to regain compliance.

## SEC filing metadata
- accession: 0001437749-23-000652
- form_type: 8-K
- cik: 0001029125
- company_name: Panbela Therapeutics, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774923000652/0001437749-23-000652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774923000652/pbla20230106_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-000652
- JSON: https://secwatch.observer/filing/0001437749-23-000652.json
- Plain text: https://secwatch.observer/filing/0001437749-23-000652.txt

## Key facts
- Listing & Compliance Notices
  Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)(iii)
  source text: January 3, 2023, the Company received a letter from the Staff notifying it that, as of December 30, 2022, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days during the Minimum Bid Price Rule Compliance Period and, therefore, as contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Company’s common stock will be delisted from The Nasdaq Capital Market. Nasdaq indicated that it would suspend trading in the Company’s common stock at the opening of business on January 12, 2023 and file a Form 25-NSE with the Securities and Exchange Commiss
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923000652/0001437749-23-000652-index.htm
- Listing & Compliance Notices
  Panbela Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: August 19, 2022, Panbela Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. The Company submitted to Nasdaq a plan to regain compliance with the Minimum Equity Rule and was grant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774923000652/0001437749-23-000652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.